Bladder Cancer: Epidemiological, Clinical, and Therapeutic Aspects in Hospitals of Ziguinchor City

Aboubacar Traore; Modou Diop Ndiaye; Massaer Diouf; Ibrahima Diallo; Mohamed Doukoure; Omar Sow; Boubacar Fall

doi:doi:10.11648/j.ijcu.20250902.27

Research Article |

| Peer-Reviewed

Bladder Cancer: Epidemiological, Clinical, and Therapeutic Aspects in Hospitals of Ziguinchor City

Aboubacar Traore^*

, Modou Diop Ndiaye, Massaer Diouf, Ibrahima Diallo, Mohamed Doukoure, Omar Sow, Boubacar Fall

Published in International Journal of Clinical Urology (Volume 9, Issue 2)

Received: 26 November 2025 Accepted: 12 December 2025 Published: 26 December 2025

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Introduction: Bladder cancer is one of the most common urological malignancies, with a high global incidence in men. Studies conducted in Dakar report a prevalence of 2.5% according to histopathological findings. Transurethral resection of the bladder (TURB) remains the cornerstone of treatment. The aim of this study was to describe the epidemiological, clinical, and therapeutic aspects of bladder cancer in urology departments in Ziguinchor. Methods: We conducted a retrospective, descriptive, and analytical study over five years (January 1, 2018 – December 31, 2023), including all bladder cancer cases managed in our departments. Patient data were collected from medical records. Chi-square (χ2) and Student’s t-tests were applied, with significance set at p < 0.05. Variables included epidemiological, clinical, paraclinical, TURB-related, therapeutic, and outcome data. Results: Bladder cancer was the second most frequent urological malignancy (22%), after prostate cancer (69%). The mean age of patients was 62.4 years with a male predominance 69.2% (n = 18). Median time for consultation was 60 days. Hematuria was reported in 88.5% (n = 23). General condition was poor Eastern Cooperative Oncology Group (ECOG3) in 58% of patients. Smoking was present in 34.6% (n = 9). Urinary tract ultrasound was performed in 84.6% (n = 22) and CT urography in 61.5% (n = 16). Cystoscopy and TURB were systematically performed, within an average of 3 months. Complications included hematuria and renal impairment. Urothelial carcinoma was found in 69.2% (n = 18). Total cystectomy was performed in 15.4% (n = 4). Overall, 50% (n = 13) of patients died. During follow-up, 15.4% (n = 4) were lost to follow-up at 3 months. Median survival was 4 months. Conclusion: Bladder cancer is prevalent among older adults. Cystoscopy was systematically performed in our study. TURB remains the cornerstone of treatment. Prognosis is poor at advanced stages.

Published in	International Journal of Clinical Urology (Volume 9, Issue 2)
DOI	10.11648/j.ijcu.20250902.27
Page(s)	204-208
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2025. Published by Science Publishing Group

Keywords

Bladder Cancer, Cystoscopy, TURB

References

[1]	P Gontero, A Birtle, O Capoun, E Compérat, JL Dominguez-Escrig, F Liedberg, and al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) – A Summary of the 2024 Guidelines Update. Eur Urol 2024; 86: 531–49. https://doi.org/10.1016/j.eururo.2024.07.027
[2]	M Rouprêt. French recommendations from the AFU oncology committee – update 2022–2024. Prog Urol 2022; 32: 1009. https://doi.org/10.1016/j.purol.2022.10.001
[3]	F Bray, J Ferlay, I Soerjomataram, RL Siegel, LA Torre, A Jemal. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424. https://doi.org/10.3322/caac.21492
[4]	Bladder cancer statistics. World Cancer Research Fund. https://www.wcrf.org/preventing-cancer/cancer-statistics/bladder-cancer-statistics/ (accessed November 8, 2025).
[5]	B Diao, T Amath, B Fall, PA Fall, MJ Diémé, NN Steevy, and al. Bladder cancers in Senegal: epidemiological, clinical, and histological characteristics. Prog Urol 2008; 18: 445–8. https://doi.org/10.1016/j.purol.2008.04.016
[6]	HAA Amin, MH Kobaisi, RM Samir. Schistosomiasis and bladder cancer in Egypt: truths and myths. Open Access Maced J Med Sci 2019; 7: 4023–9. https://doi.org/10.3889/oamjms.2019.857
[7]	M Traore, M Jalloh, M Yevi, M Ndoye, I Labou, L Niang, and al. Transurethral resection of bladder tumors at the Grand Yoff General Hospital: about 141 cases. Uro’Andro 2018; 1: 463–7.
[8]	S Larré, P Leon, A El Bakri. Bladder cancer: diagnosis and treatment principles. EMC - Urol 2016; 9: 1–17.
[9]	J Mushtaq, R Thurairaja, R Nair. Bladder cancer. Surgery (Oxford) 2019; 37: 529–37. https://doi.org/10.1016/j.mpsur.2019.07.003
[10]	NF Abbas, MR Aoude, HR Kourie, HO Al-Shamsi. Uncovering the epidemiology of bladder cancer in the Arab world: a review of risk factors, molecular mechanisms, and clinical features. Asian J Urol 2024; 11: 406–22. https://doi.org/10.1016/j.ajur.2023.10.001
[11]	R Salah, N Harir, S Zeggai, F Sellam, NM Merabent, S Moullessehoul, and al. Urological cancers in Algeria: histo-epidemiological profile of 348 cases. J Afr Cancer 2015; 7: 126–31. https://doi.org/10.1007/s12558-014-0342-9
[12]	M Sow, B Nkégoum, J-LE Oyono, N Garoua, A Nzokou. Epidemiological and histological features of urogenital tumors in Cameroon. Prog Urol 2006; 16: 36–9.
[13]	R Mastroianni, G Tuderti, M Ferriero, U Anceschi, AM Bove, A Brassetti, and al. Robot-assisted radical cystectomy with totally intracorporeal urinary diversion versus open radical cystectomy: 3-year outcomes from a randomized controlled trial. Eur Urol 2024; 85: 422–30. https://doi.org/10.1016/j.eururo.2024.01.018
[14]	JN Kulkarni. Perioperative morbidity of radical cystectomy: a review. Indian J Urol 2011; 27: 226–32. https://doi.org/10.4103/0970-1591.82842
[15]	O Gaye, M Jalloh, M Ndoye, A Tall, NM Thiam, C Dial, and al. Bladder cancer in Senegal: what’s new? African Urology 2023; 3: 14–8. https://doi.org/10.36303/AUJ.0061
[16]	I Diallo, I Diamé, C Diouf, S Faye, A Thiam, A Yaya, and al. Urogenital cancers in peripheral regions of Senegal: a study of 156 cases. African Journal of Urology 2021; 27: 9–16. https://doi.org/10.21608/afju.2021.9275
[17]	A Collado, GE Chéchile, J Salvador, J Vicente. Early complications of endoscopic treatment for superficial bladder tumors. J Urol 2000; 164: 1529–32. https://doi.org/10.1016/S0022-5347(05)67021-8
[18]	A Pycha, M Lodde, L Lusuardi, S Palermo, D Signorello, A Galantini, and al. Teaching transurethral resection of the bladder: still a challenge? Urology 2003; 62: 46–8. https://doi.org/10.1016/s0090-4295(03)00128-6
[19]	F-I Hsieh, T-S Hwang, Y-C Hsieh, H-C Lo, C-T Su, H-S Hsu, and al. Risk of erectile dysfunction induced by arsenic exposure through well water consumption in Taiwan. Environ Health Perspect 2008; 116: 532–6. https://doi.org/10.1289/ehp.10930
[20]	CN Sternberg, I Skoneczna, JM Kerst, P Albers, SD Fossa, M Agerbaek, and al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomized phase 3 trial. Lancet Oncol 2015; 16: 76–86. https://doi.org/10.1016/S1470-2045(14)71160-X
[21]	HW Herr. Conservative management of muscle-infiltrating bladder cancer: prospective experience. J Urol 1987; 138: 1162–3. https://doi.org/10.1016/s0022-5347(17)43535-x

Cite This Article

Plain Text BibTeX RIS

APA Style

Traore, A., Ndiaye, M. D., Diouf, M., Diallo, I., Doukoure, M., et al. (2025). Bladder Cancer: Epidemiological, Clinical, and Therapeutic Aspects in Hospitals of Ziguinchor City. International Journal of Clinical Urology, 9(2), 204-208. https://doi.org/10.11648/j.ijcu.20250902.27

Copy | Download

ACS Style

Traore, A.; Ndiaye, M. D.; Diouf, M.; Diallo, I.; Doukoure, M., et al. Bladder Cancer: Epidemiological, Clinical, and Therapeutic Aspects in Hospitals of Ziguinchor City. Int. J. Clin. Urol. 2025, 9(2), 204-208. doi: 10.11648/j.ijcu.20250902.27

Copy | Download

AMA Style

Traore A, Ndiaye MD, Diouf M, Diallo I, Doukoure M, et al. Bladder Cancer: Epidemiological, Clinical, and Therapeutic Aspects in Hospitals of Ziguinchor City. Int J Clin Urol. 2025;9(2):204-208. doi: 10.11648/j.ijcu.20250902.27

Copy | Download

@article{10.11648/j.ijcu.20250902.27,
  author = {Aboubacar Traore and Modou Diop Ndiaye and Massaer Diouf and Ibrahima Diallo and Mohamed Doukoure and Omar Sow and Boubacar Fall},
  title = {Bladder Cancer: Epidemiological, Clinical, and Therapeutic Aspects in Hospitals of Ziguinchor City},
  journal = {International Journal of Clinical Urology},
  volume = {9},
  number = {2},
  pages = {204-208},
  doi = {10.11648/j.ijcu.20250902.27},
  url = {https://doi.org/10.11648/j.ijcu.20250902.27},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcu.20250902.27},
  abstract = {Introduction: Bladder cancer is one of the most common urological malignancies, with a high global incidence in men. Studies conducted in Dakar report a prevalence of 2.5% according to histopathological findings. Transurethral resection of the bladder (TURB) remains the cornerstone of treatment. The aim of this study was to describe the epidemiological, clinical, and therapeutic aspects of bladder cancer in urology departments in Ziguinchor. Methods: We conducted a retrospective, descriptive, and analytical study over five years (January 1, 2018 – December 31, 2023), including all bladder cancer cases managed in our departments. Patient data were collected from medical records. Chi-square (χ2) and Student’s t-tests were applied, with significance set at p < 0.05. Variables included epidemiological, clinical, paraclinical, TURB-related, therapeutic, and outcome data. Results: Bladder cancer was the second most frequent urological malignancy (22%), after prostate cancer (69%). The mean age of patients was 62.4 years with a male predominance 69.2% (n = 18). Median time for consultation was 60 days. Hematuria was reported in 88.5% (n = 23). General condition was poor Eastern Cooperative Oncology Group (ECOG3) in 58% of patients. Smoking was present in 34.6% (n = 9). Urinary tract ultrasound was performed in 84.6% (n = 22) and CT urography in 61.5% (n = 16). Cystoscopy and TURB were systematically performed, within an average of 3 months. Complications included hematuria and renal impairment. Urothelial carcinoma was found in 69.2% (n = 18). Total cystectomy was performed in 15.4% (n = 4). Overall, 50% (n = 13) of patients died. During follow-up, 15.4% (n = 4) were lost to follow-up at 3 months. Median survival was 4 months. Conclusion: Bladder cancer is prevalent among older adults. Cystoscopy was systematically performed in our study. TURB remains the cornerstone of treatment. Prognosis is poor at advanced stages.},
 year = {2025}
}

Copy | Download

TY  - JOUR
T1  - Bladder Cancer: Epidemiological, Clinical, and Therapeutic Aspects in Hospitals of Ziguinchor City
AU  - Aboubacar Traore
AU  - Modou Diop Ndiaye
AU  - Massaer Diouf
AU  - Ibrahima Diallo
AU  - Mohamed Doukoure
AU  - Omar Sow
AU  - Boubacar Fall
Y1  - 2025/12/26
PY  - 2025
N1  - https://doi.org/10.11648/j.ijcu.20250902.27
DO  - 10.11648/j.ijcu.20250902.27
T2  - International Journal of Clinical Urology
JF  - International Journal of Clinical Urology
JO  - International Journal of Clinical Urology
SP  - 204
EP  - 208
PB  - Science Publishing Group
SN  - 2640-1355
UR  - https://doi.org/10.11648/j.ijcu.20250902.27
AB  - Introduction: Bladder cancer is one of the most common urological malignancies, with a high global incidence in men. Studies conducted in Dakar report a prevalence of 2.5% according to histopathological findings. Transurethral resection of the bladder (TURB) remains the cornerstone of treatment. The aim of this study was to describe the epidemiological, clinical, and therapeutic aspects of bladder cancer in urology departments in Ziguinchor. Methods: We conducted a retrospective, descriptive, and analytical study over five years (January 1, 2018 – December 31, 2023), including all bladder cancer cases managed in our departments. Patient data were collected from medical records. Chi-square (χ2) and Student’s t-tests were applied, with significance set at p < 0.05. Variables included epidemiological, clinical, paraclinical, TURB-related, therapeutic, and outcome data. Results: Bladder cancer was the second most frequent urological malignancy (22%), after prostate cancer (69%). The mean age of patients was 62.4 years with a male predominance 69.2% (n = 18). Median time for consultation was 60 days. Hematuria was reported in 88.5% (n = 23). General condition was poor Eastern Cooperative Oncology Group (ECOG3) in 58% of patients. Smoking was present in 34.6% (n = 9). Urinary tract ultrasound was performed in 84.6% (n = 22) and CT urography in 61.5% (n = 16). Cystoscopy and TURB were systematically performed, within an average of 3 months. Complications included hematuria and renal impairment. Urothelial carcinoma was found in 69.2% (n = 18). Total cystectomy was performed in 15.4% (n = 4). Overall, 50% (n = 13) of patients died. During follow-up, 15.4% (n = 4) were lost to follow-up at 3 months. Median survival was 4 months. Conclusion: Bladder cancer is prevalent among older adults. Cystoscopy was systematically performed in our study. TURB remains the cornerstone of treatment. Prognosis is poor at advanced stages.
VL  - 9
IS  - 2
ER  -

Copy | Download

Author Information

Aboubacar Traore

Urology Department, Peace Hospital, Ziguinchor, Senegal;Department of Surgery, Assane Seck University, Ziguinchor, Senegal

Contact Email

http://orcid.org/0009-0001-5177-3877
Modou Diop Ndiaye

Urology Department, Peace Hospital, Ziguinchor, Senegal;Department of Surgery, Assane Seck University, Ziguinchor, Senegal
Massaer Diouf

Urology Department, Peace Hospital, Ziguinchor, Senegal;Department of Surgery, Assane Seck University, Ziguinchor, Senegal
Ibrahima Diallo

Department of Surgery, Assane Seck University, Ziguinchor, Senegal;Urology Department, Regional Hospital, Ziguinchor, Senegal
Mohamed Doukoure

Urology Department, Peace Hospital, Ziguinchor, Senegal;Department of Surgery, Gaston Berger University (UGB), Saint-Louis, Senegal
Omar Sow

Department of Surgery, Assane Seck University, Ziguinchor, Senegal
Boubacar Fall

Urology Department, Peace Hospital, Ziguinchor, Senegal;Department of Surgery, Assane Seck University, Ziguinchor, Senegal

Download PDF

Submit an Article

Sections

Plain Text BibTeX RIS

APA Style

Traore, A., Ndiaye, M. D., Diouf, M., Diallo, I., Doukoure, M., et al. (2025). Bladder Cancer: Epidemiological, Clinical, and Therapeutic Aspects in Hospitals of Ziguinchor City. International Journal of Clinical Urology, 9(2), 204-208. https://doi.org/10.11648/j.ijcu.20250902.27

Copy | Download

ACS Style

Traore, A.; Ndiaye, M. D.; Diouf, M.; Diallo, I.; Doukoure, M., et al. Bladder Cancer: Epidemiological, Clinical, and Therapeutic Aspects in Hospitals of Ziguinchor City. Int. J. Clin. Urol. 2025, 9(2), 204-208. doi: 10.11648/j.ijcu.20250902.27

Copy | Download

AMA Style

Traore A, Ndiaye MD, Diouf M, Diallo I, Doukoure M, et al. Bladder Cancer: Epidemiological, Clinical, and Therapeutic Aspects in Hospitals of Ziguinchor City. Int J Clin Urol. 2025;9(2):204-208. doi: 10.11648/j.ijcu.20250902.27

Copy | Download

@article{10.11648/j.ijcu.20250902.27,
  author = {Aboubacar Traore and Modou Diop Ndiaye and Massaer Diouf and Ibrahima Diallo and Mohamed Doukoure and Omar Sow and Boubacar Fall},
  title = {Bladder Cancer: Epidemiological, Clinical, and Therapeutic Aspects in Hospitals of Ziguinchor City},
  journal = {International Journal of Clinical Urology},
  volume = {9},
  number = {2},
  pages = {204-208},
  doi = {10.11648/j.ijcu.20250902.27},
  url = {https://doi.org/10.11648/j.ijcu.20250902.27},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcu.20250902.27},
  abstract = {Introduction: Bladder cancer is one of the most common urological malignancies, with a high global incidence in men. Studies conducted in Dakar report a prevalence of 2.5% according to histopathological findings. Transurethral resection of the bladder (TURB) remains the cornerstone of treatment. The aim of this study was to describe the epidemiological, clinical, and therapeutic aspects of bladder cancer in urology departments in Ziguinchor. Methods: We conducted a retrospective, descriptive, and analytical study over five years (January 1, 2018 – December 31, 2023), including all bladder cancer cases managed in our departments. Patient data were collected from medical records. Chi-square (χ2) and Student’s t-tests were applied, with significance set at p < 0.05. Variables included epidemiological, clinical, paraclinical, TURB-related, therapeutic, and outcome data. Results: Bladder cancer was the second most frequent urological malignancy (22%), after prostate cancer (69%). The mean age of patients was 62.4 years with a male predominance 69.2% (n = 18). Median time for consultation was 60 days. Hematuria was reported in 88.5% (n = 23). General condition was poor Eastern Cooperative Oncology Group (ECOG3) in 58% of patients. Smoking was present in 34.6% (n = 9). Urinary tract ultrasound was performed in 84.6% (n = 22) and CT urography in 61.5% (n = 16). Cystoscopy and TURB were systematically performed, within an average of 3 months. Complications included hematuria and renal impairment. Urothelial carcinoma was found in 69.2% (n = 18). Total cystectomy was performed in 15.4% (n = 4). Overall, 50% (n = 13) of patients died. During follow-up, 15.4% (n = 4) were lost to follow-up at 3 months. Median survival was 4 months. Conclusion: Bladder cancer is prevalent among older adults. Cystoscopy was systematically performed in our study. TURB remains the cornerstone of treatment. Prognosis is poor at advanced stages.},
 year = {2025}
}

Copy | Download

TY  - JOUR
T1  - Bladder Cancer: Epidemiological, Clinical, and Therapeutic Aspects in Hospitals of Ziguinchor City
AU  - Aboubacar Traore
AU  - Modou Diop Ndiaye
AU  - Massaer Diouf
AU  - Ibrahima Diallo
AU  - Mohamed Doukoure
AU  - Omar Sow
AU  - Boubacar Fall
Y1  - 2025/12/26
PY  - 2025
N1  - https://doi.org/10.11648/j.ijcu.20250902.27
DO  - 10.11648/j.ijcu.20250902.27
T2  - International Journal of Clinical Urology
JF  - International Journal of Clinical Urology
JO  - International Journal of Clinical Urology
SP  - 204
EP  - 208
PB  - Science Publishing Group
SN  - 2640-1355
UR  - https://doi.org/10.11648/j.ijcu.20250902.27
AB  - Introduction: Bladder cancer is one of the most common urological malignancies, with a high global incidence in men. Studies conducted in Dakar report a prevalence of 2.5% according to histopathological findings. Transurethral resection of the bladder (TURB) remains the cornerstone of treatment. The aim of this study was to describe the epidemiological, clinical, and therapeutic aspects of bladder cancer in urology departments in Ziguinchor. Methods: We conducted a retrospective, descriptive, and analytical study over five years (January 1, 2018 – December 31, 2023), including all bladder cancer cases managed in our departments. Patient data were collected from medical records. Chi-square (χ2) and Student’s t-tests were applied, with significance set at p < 0.05. Variables included epidemiological, clinical, paraclinical, TURB-related, therapeutic, and outcome data. Results: Bladder cancer was the second most frequent urological malignancy (22%), after prostate cancer (69%). The mean age of patients was 62.4 years with a male predominance 69.2% (n = 18). Median time for consultation was 60 days. Hematuria was reported in 88.5% (n = 23). General condition was poor Eastern Cooperative Oncology Group (ECOG3) in 58% of patients. Smoking was present in 34.6% (n = 9). Urinary tract ultrasound was performed in 84.6% (n = 22) and CT urography in 61.5% (n = 16). Cystoscopy and TURB were systematically performed, within an average of 3 months. Complications included hematuria and renal impairment. Urothelial carcinoma was found in 69.2% (n = 18). Total cystectomy was performed in 15.4% (n = 4). Overall, 50% (n = 13) of patients died. During follow-up, 15.4% (n = 4) were lost to follow-up at 3 months. Median survival was 4 months. Conclusion: Bladder cancer is prevalent among older adults. Cystoscopy was systematically performed in our study. TURB remains the cornerstone of treatment. Prognosis is poor at advanced stages.
VL  - 9
IS  - 2
ER  -

Copy | Download